Table 2b. Likelihood of receiving “standard” treatment (surgery or definitive thoracic radiation) for stage III NSCLC.
| Univariate OR (95% CI) |
Univariate P-Value |
Multivariate OR (95% CI) |
Multivariate P-Value |
|
|---|---|---|---|---|
| Age, no. (%) | ||||
| < 65 | Reference | 0.06 | Reference | 0.05 |
| ≥ 65 | 0.55 (0.29-1.04) | 0.39 (0.16-0.98) | ||
| Gender, no. (%) | ||||
| Male | Reference | 0.02 | Reference | 0.07 |
| Female | 2.28 (1.15-4.40) | 1.95 (0.95-4.00) | ||
| Race, no. (%) | ||||
| White, non-Hispanic | Reference | 0.11 | Reference | 0.23 |
| Other | 0.60 (0.32-1.13) | 0.67 (0.33-1.31) | ||
| Insurance, no. (%) | ||||
| Private | Reference | 0.12 | Reference | 0.09 |
| Medicare | 0.46 (0.18-1.21) | 0.85 (0.27-2.65) | ||
| Indigent | 0.38 (0.15-0.96) | 0.38 (0.14-1.00) | ||
| Histology, no. (%) | ||||
| Adenocarcinoma | Reference | 0.93 | Reference | 0.79 |
| Squamous Cell | 0.88 (0.43-1.79) | 1.32 (0.60-2.89) | ||
| Other * | 0.91 (0.39-2.14) | 1.17 (0.46-2.95) |
*
Includes patients with large cell, adenosquamous or unspecified